

Nepafenac

Cat. No.: HY-17357

CAS No.: 78281-72-8

Molecular Formula: C₁₅H₁₄N₂O₂


Molecular Weight: 254.28

Target: COX; Bacterial

Pathway: Immunology/Inflammation; Anti-infection

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (393.27 mM; Need ultrasonic)

Preparing Stock Solutions	Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.9327 mL	19.6634 mL	39.3267 mL
	5 mM	0.7865 mL	3.9327 mL	7.8653 mL
	10 mM	0.3933 mL	1.9663 mL	3.9327 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	Nepafenac(AHR 9434; AL 6515; Nevanac) is a selective COX-2 inhibitor; is prodrug of Amfenac. IC ₅₀ value: Target: COX-2 Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) that is routinely used in ophthalmology to control pain following cataract surgery.	
IC ₅₀ & Target	COX-1 64.3 µM (IC ₅₀)	COX-2

REFERENCES

[1]. Gamache DA, Graff G, Brady MT et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70.

[2]. Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000 Aug;24(4):371-84.

[3]. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. *Curr Med Res Opin.* 2006 Feb;22(2):397-404.

[4]. Marshall JC, Fernandes BF, Di Cesare S et al. The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. *Carcinogenesis.* 2007 Sep;28(9):2053-8.

[5]. Singh R, Alpern L, Jaffe GJ et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. *Clin Ophthalmol.* 2012;6:1259-69.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA